Physiomics (GB:PYC) has released an update.
Physiomics PLC has partnered with DoseMe to integrate its personalized dosing software into the DoseMeRx platform, enhancing precision in chemotherapy and GCSF dosing for cancer treatments. This collaboration builds on past successful grants and aims to provide decision support for clinicians, with plans to make the software available for research use in the second half of 2024. Physiomics is also exploring ways to simplify blood sampling for patients, considering options like new diagnostic devices and possible business structure changes to focus on this software development.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
